HemaQuestTM is a Seattle-based biopharmaceutical company developing proprietary small molecules targeting specific genes that enable the treatment of serious and life threatening hematologic disorders. Currently, the Company has two therapeutics in Phase 2 clinical development - HQK-1001 for hemoglobin disorders such as sickle cell disease and beta thalassemia, and HQK-1004 for viral-related cancers. It was founded in late 2007 by leading hematologists with funding from top tier investors, including De Novo Ventures, Forward Ventures, and Lilly Ventures, In 2010 they were joined by additional investors, Aberdare Ventures and Latterell Venture Partners.

Technology Overview

HemaQuest's Founders discovered that short chain fatty acids (SCFA) possess a variety of important biological effects of therapeutic benefit in treating patients with a range of hematologic disorders. Learn More...

Hemoglobin Disorders

At present, there are limited therapeutic options available for patients suffering from sickle cell disease and beta thalassemia. HemaQuest is developing new therapies for these chronic and debilitating illnesses. Learn More...

Viral Malignancies

HemaQuest is developing a clinical program to evaluate HQK-1004 in patients with lymphoma or lymphoproliferative disorders (LPD) that are associated with Epstein Barr virus (EBV). Learn More...